Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 191

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 191
---
 to participating lenders. In
addition, pursuant to the October 2024 Addendum, we agreed to pay the participating lenders at maturity an additional aggregate
amount of 340,000 as a risk premium, and upon the occurrence of an initial public offering based on a pre money valuation of $5.15
million, the 2020 CLAs shall be automatically converted into 609,888 Ordinary Shares and the Additional Amount in addition to the
risk premium and the Interest Amount (each as defined therein) shall be automatically converted into 553,640 Ordinary
Shares.

Other Financings

Between October 2024
and November 2024, we entered into bridge loan agreements, or the Bridge Loans, pursuant to which we obtained a bridge loan in the
total amount of $350,000 from certain lenders (out of which, an amount of $100,000 was received subsequent to December 31, 2024),
including Dr. Ehud Geller, the chairman and a member of our board of directors, and Pini Ben Elazar, a director nominee. The Bridge
Loans shall bear interest at 8% per annum until maturity and we agreed to pay the lenders an additional risk premium equal to 30% of
their respective loan amount. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans may be extended beyond
March 31, 2025 and until June 30, 2025, subject to the Registration Statement effectiveness not later than March 31, 2025 and the
fulfillment of additional cumulative conditions. During September 2025, the Bridge Loans have been extended until November 30, 2025.
Furthermore, upon the occurrence of an initial public offering of our securities for a total offering of not less than $6,000,000 (a
“Qualified IPO”), the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to
two times their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price
per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public
offering. On July 1, 2025, we entered into an amendment to the Bridge Loan such that the Bridge Loan lenders shall be granted
warrants to purchase up to 140,000 Ordinary Shares following the consummation of this offering.

Between December 2023
and January